Signaling Through the Erythropoietin Receptor Affects Angiogenesis in Retinovascular Disease

Purpose Exogenous erythropoietin (EPO) is being considered for tissue protection and angiogenesis in retinal vascular diseases. However, studies are limited by insufficient tools to address signaling effects through the EPO receptor (EPOR). We used a humanized mouse model of hypoactive EPOR signaling to test the hypothesis that EPOR signaling supports angiogenesis in retinovascular diseases. Methods Humanized Knockin EPOR mice (hWtEPOR) with hypoactive EPOR signaling were compared to littermate wild-type mice (WT). Postnatal day (p)7 mice of each genotype were exposed to 75% oxygen for five days, followed by 21% oxygen in the oxygen-induced retinopathy model (OIR) and compared to room-air (RA)–raised pups. At time points after OIR, pups were sacrificed, and flat-mounted, lectin-stained retinas were analyzed for central avascular area or intravitreal neovascular area (IVNV). Flash-frozen retinas were analyzed for angiogenic protein (Epo, VEGF, p-Stat3) and gene (Vegfa, Kdr, Epo, Hif1α, Hif2α) expression levels. Results In OIR, hWtEPOR mice had increased AVA compared with WT at p8, p12, and p17, but there was no difference in IVNV between hWtEPOR and WT mice at p17. Although VEGF and p-STAT3 proteins were increased in WT at p17 OIR, there were no differences in retinal angiogenic factor expression levels between hWtEPOR and WT OIR at p17 despite similar areas of IVNV. Conclusions Our data support the hypothesis that EPOR signaling was associated with regrowth of vascularization following oxygen-induced capillary dropout and played a role in intravitreal angiogenesis. Additional study of EPOR signaling regulation on other angiogenic factor pathways may be considered.

[1]  M. Hartnett,et al.  Erythropoietin Receptor Signaling Supports Retinal Function after Vascular Injury. , 2020, The American journal of pathology.

[2]  Phuong T. Vu,et al.  A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants. , 2020, The New England journal of medicine.

[3]  M. Yaseri,et al.  Combination of intravitreal bevacizumab and erythropoietin versus intravitreal bevacizumab alone for refractory diabetic macular edema: a randomized double-blind clinical trial , 2019, Graefe's Archive for Clinical and Experimental Ophthalmology.

[4]  Lois E. H. Smith,et al.  Erythropoietin serum levels, versus anaemia as risk factors for severe retinopathy of prematurity , 2018, Pediatric Research.

[5]  T. Kafri,et al.  Gene therapy knockdown of VEGFR2 in retinal endothelial cells to treat retinopathy , 2018, Angiogenesis.

[6]  P. Hüppi,et al.  Long-term neuroprotective effect of erythropoietin on executive functions in very preterm children (EpoKids): protocol of a prospective follow-up study , 2018, BMJ Open.

[7]  D. Ribatti,et al.  Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma , 2018, Annals of Hematology.

[8]  R. Heinrich,et al.  Alternative Erythropoietin Receptors in the Nervous System , 2018, Journal of clinical medicine.

[9]  J. Prchal,et al.  Erythropoietin Signaling Increases Choroidal Macrophages and Cytokine Expression, and Exacerbates Choroidal Neovascularization , 2018, Scientific Reports.

[10]  N. Lois,et al.  Erythropoietin in diabetic retinopathy , 2017, Vision Research.

[11]  P. Solár,et al.  Erythropoietin and Its Angiogenic Activity , 2017, International journal of molecular sciences.

[12]  M. Martinez-Castellanos,et al.  Vascular changes on fluorescein angiography of premature infants with low risk of retinopathy of prematurity after high oxygen exposure , 2017, International Journal of Retina and Vitreous.

[13]  U. Schiefer,et al.  Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial—study protocol , 2016, BMJ Open.

[14]  H. Votavova,et al.  Delayed hemoglobin switching and perinatal neocytolysis in mice with gain-of-function erythropoietin receptor , 2015, Journal of molecular medicine.

[15]  P. Heagerty,et al.  Neuroprotective potential of erythropoietin in neonates; design of a randomized trial , 2015, Maternal Health, Neonatology and Perinatology.

[16]  Zhihong Yang,et al.  VEGFA activates erythropoietin receptor and enhances VEGFR2-mediated pathological angiogenesis. , 2014, The American journal of pathology.

[17]  Sara R. Savage,et al.  Hypoxia-induced expression of VEGF splice variants and protein in four retinal cell types. , 2013, Experimental eye research.

[18]  J. Flannery,et al.  Short hairpin RNA-mediated knockdown of VEGFA in Müller cells reduces intravitreal neovascularization in a rat model of retinopathy of prematurity. , 2013, The American journal of pathology.

[19]  B. Chang,et al.  Survey of common eye diseases in laboratory mouse strains. , 2013, Investigative ophthalmology & visual science.

[20]  V. Narendran,et al.  Aggressive posterior retinopathy of prematurity in large preterm babies in South India , 2012, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[21]  A. Cerami,et al.  The Receptor That Tames the Innate Immune Response , 2012, Molecular medicine.

[22]  Michael H. Elliott,et al.  Müller Cell-Derived VEGF Is Essential for Diabetes-Induced Retinal Inflammation and Vascular Leakage , 2010, Diabetes.

[23]  N. Petrovsky,et al.  Association between erythropoietin gene polymorphisms and diabetic retinopathy. , 2010, Archives of ophthalmology.

[24]  S. Tsang,et al.  Erythropoetin receptor expression in the human diabetic retina , 2009, BMC Research Notes.

[25]  Lois E. H. Smith,et al.  Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. , 2009, Investigative ophthalmology & visual science.

[26]  Lois E. H. Smith,et al.  Erythropoietin deficiency decreases vascular stability in mice. , 2008, The Journal of clinical investigation.

[27]  J. Nielsen,et al.  Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor , 2007, Journal of Neuroscience Methods.

[28]  K. Fleming,et al.  Dimerization of the erythropoietin receptor transmembrane domain in micelles. , 2007, Journal of molecular biology.

[29]  J. C. Kim,et al.  Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy , 2007, Eye.

[30]  A. Cerami,et al.  Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. , 2006, Kidney international.

[31]  C. Begley,et al.  Anti-Epo receptor antibodies do not predict Epo receptor expression. , 2006, Blood.

[32]  S. Masuda,et al.  Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. , 2005, The New England journal of medicine.

[33]  D. Barber,et al.  Turning cells red: signal transduction mediated by erythropoietin. , 2005, Trends in cell biology.

[34]  T. Townes,et al.  Mouse model of congenital polycythemia: Homologous replacement of murine gene by mutant human erythropoietin receptor gene. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Rudolf Jaenisch,et al.  Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor , 1995, Cell.

[36]  Lois E. H. Smith,et al.  Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Lois E. H. Smith,et al.  Oxygen-induced retinopathy in the mouse. , 1994, Investigative ophthalmology & visual science.